# An Open-Label, Multi-Center Trial in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis

> **NCT00725348** · PHASE2 · COMPLETED · sponsor: **Stiefel, a GSK Company** · enrollment: 19 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Talarozole

## Key facts

- **NCT ID:** NCT00725348
- **Lead sponsor:** Stiefel, a GSK Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2005-03
- **Final completion:** 2006-12
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2011-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00725348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00725348, "An Open-Label, Multi-Center Trial in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00725348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*